Skip to main content
. Author manuscript; available in PMC: 2019 Dec 1.
Published in final edited form as: Cell Immunol. 2018 Oct 13;334:87–98. doi: 10.1016/j.cellimm.2018.10.003

Table 1:

Summary of Single Agent Checkpoint Inhibitor Trials. (ORR: overall response rate, DC: disease control rate, PR: partial response, SD: stable disease).

Agent Target Trial Population N (MM Patients) Overall Endpoint Response Rate (%) # of Myeloma Responders(%) Response Rate MM(%) Best Response in MM patients Ref
Ipilimumab CTLA4 Relapsed Hematologic Malignancies 22 (1) ORR 32 1 100 PR 108
Pidilizumab PD-1 Advanced Hematologic Malignancies 17 (1) DC 33 1 100 PR 109
Nivolumab PD-1 Relapsed Refractory Hematologic Malignancies 81 (27) DC 16 1 4 SD 110
Pembrolizumab PD-1 Relapsed Refractory MM 30 (30) ORR 0 0 0 SD 111